Finally, a meta-analysis of 14 studies in patients with RA, adjusted for hypertension, concluded that DMARDs were associated with an increased risk of MACE relative to TNF-α inhibitor therapy [OR: 1.58 (95% CI: 1.16–2.15); I2 = 16%], effect maintained in presence or absence of MTX.268. Here, TNF is linked to rheumatoid arthritis.